AIOMEGA® announced the first prescribed clinical use of AIO BREATHE® mandibular repositioning device, FDA-cleared for ...

SARASOTA, FL, UNITED STATES, January 28, 2026 / EINPresswire.com / — Identifyn ®, a leader in super-resolution applications ...

As integrated health technologies increasingly shape the future of heart failure management, this paper provides ...

G-protein-coupled receptors (GPCRs) are one of the largest families of cell surface proteins in the human body that recognize hormones, neurotransmitters, and drugs. These receptors regulate a wide ...

I think it has both implications for the civilian setting, particularly in longer transport or resource-limited areas," Dr. Adit Ginde said.

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

With data from a mid-stage trial showing weight loss of up to 12.3% at 28 weeks in patients treated with PF’3944, "Pfizer is moving full speed into obesity clinical development,” BMO Capital Markets ...

Analysts expect the company to post earnings of $4.76, representing a 10.4% drop from the corresponding period of the previous year. Revenue is expected to rise 4% to $9.46B. Over the last 3 months, ...

Ascletis Pharma has posted 7.7% weight loss for the highest dose of its own entrant in the highly contested oral GLP-1 race. The Chinese biotech evaluated three different once-daily doses of its oral ...